Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Phase 2 N=127 Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Breast Cancer · Lung Cancer · Prostate Cancer
Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants
Phase 3 N=41,181 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
N/A N=8,790 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
N/A N=521 Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults
Preference, Patient
Primary: Prevalence — 16 Participants
Phase 2 N=460 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
N/A N=391 Impact of Prevnar 13 on Ear Infections in Children
Acute Otitis Media · Mastoiditis
Primary: Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 1 — 5.9; 0.7; 31.9; 2.2 percentage of isolates
N/A N=50 Effect of Obesity on Immune Response to Pneumovax 23
Obesity
Primary: Anti-pneumococcal Antibodies Between the Groups — 34.1; 19.8 titer
Phase 4 N=17 Pneumococcal Vaccines in Patients With Asthma
Asthma
Primary: Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16 — 109.8; 53.9; 142.3; 53.9 mcg/dL
Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
N/A N=239 Effect of Prevnar 13 on Ear Infections in Children
Otitis Media
Primary: Percentage of Middle Ear Fluid (MEF) Samples With Positive Results for Streptococcus Pneumoniae Serotypes 1, 3, 5, 6A, 7F, or 19A in Participants With Acute Otitis Media…
N/A N=107 Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
HIV Infections
Primary: Immunoglobulin G (IgG) Levels — 5.12; 5.17; 1.80; 1.83 Micrograms/ml
Phase 4 N=84,496 Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
Pneumonia, Pneumococcal · Pneumococcal Infections · 13-valent Pneumococcal Vaccine
Primary: Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) — 49; 90 participants — p=0.0006
Phase 2 N=346 Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
PNC Vaccine · HIV-infected Pregnant Women
Primary: Number of Women Who Experienced Various Adverse Events (AEs) — 2; 3; 4; 1 Participants
Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects
Phase 2 N=750 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Pneumococcal Immunization
Primary: Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA — 128; 127; 158; 254 Titer
Phase 3 N=2,068 Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Phase 3 N=518 Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination — 9.1; 25.4; 51.8; 78.5 Percentage of participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Phase 3 N=1,515 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 15.1; 14.0; 75.8; 68.8 Percentage of Participants
N/A N=350,399 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
HIV · Pneumonia · Infections, Pneumococcal
Primary: PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up — 167; 747 Participants
Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer
Phase 2 N=444 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 — 7.3; 3.6; 3.6; 3.2 percentage of participants
Phase 4 N=162 The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
Phase 2 N=220 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines
Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events